Emulate, Inc. Introduces DBTL Acceleration Engine for Pharmaceutical & Drug Development

As the organ-on-chip & organoids market heats up — analysts project it will reach $3.4 billion by 2028 — Emulate, Inc. has made its move. The company's platform, Emulate, human organ-on-chip technology delivering living tissue models for predictive drug testing. Emulate commercialized the organ-on-chip technology originally developed at Harvard's Wyss Institute, creating microfluidic devices lined with human primary cells or iPSC-derived cells that replicate the mechanical forces, fluid flow, and cellular microenvironment of living organs. The timing aligns with an industry shift: foundry-as-a-service models are democratizing synthetic biology. Whether Emulate, Inc. can carve out meaningful share remains to be seen, but the opportunity is clear. VP Strain Engineering and CTO professionals are actively searching for platforms that can deliver 5-10x faster design-build-test-learn cycles with AI-guided design without the integration headaches that have plagued earlier generations of digital biology.

How the Foundry Platform Works

Emulate, Inc.'s approach to organ-on-chip & organoids starts with architecture. Emulate commercialized the organ-on-chip technology originally developed at Harvard's Wyss Institute, creating microfluidic devices lined with human primary cells or iPSC-derived cells that replicate the mechanical forces, fluid flow, and cellular microenvironment of living organs. The platform's capabilities span high-throughput organoid screening, real-time tissue sensing, standardized culture protocols, disease modeling, imaging & analysis, each engineered for the high-volume, real-time processing that operations demand. Automated platforms test thousands of compounds per experiment on organoid arrays. Buyers in this segment are typically looking for 5-10x faster design-build-test-learn cycles with AI-guided design — a bar that Emulate, Inc. claims to meet through a combination of machine learning models trained on industry-specific data and integration with industry-standard systems. The question for enterprise evaluators is whether the platform can deliver these results at the scale their operations require.

On the integration front, Emulate connects with Hubrecht Organoid Technology, InSphero, Cellink, Corning Matrigel and 9 additional systems. For organ-on-chip & organoids buyers, native connectivity to industry-standard platforms is often the deciding factor — and Emulate, Inc. appears to understand this.

The Synthetic Biology Landscape

Three years ago, organ-on-chip & organoids was a niche category within digital biology. Today, it's a $3.4 billion by 2028 opportunity that every major pharmaceutical & drug development operator is evaluating. The shift has been driven by hard numbers: 500+ engineered organisms are in commercial pipelines, and early adopters are reporting 5-10x faster design-build-test-learn cycles with AI-guided design. The underlying trend — foundry-as-a-service models are democratizing synthetic biology — shows no signs of slowing. For VP Strain Engineering and CTO professionals, the question is no longer whether to invest, but which vendor to bet on. This maturation has also changed how vendors compete: the market is moving past the hype cycle and into a phase where platform reliability, integration ecosystem breadth, and demonstrable customer outcomes determine which solutions gain traction. For Emulate, Inc., this means the path to market share runs through proven deployments rather than promises.

Enterprise Considerations

Before engaging with Emulate, Inc. or any organ-on-chip & organoids vendor, pharmaceutical & drug development enterprises should establish clear evaluation criteria. The most successful deployments in this category share common prerequisites: executive sponsorship from VP Strain Engineering and CTO leadership, clean data pipelines that can feed the AI platform, and organizational readiness to act on the insights the system generates. Without these foundations, even the most capable organ-on-chip & organoids platform will underdeliver. Emulate, Inc.'s ability to help customers prepare for successful deployment — not just sell them software — will be a key differentiator.

What Comes Next for Synbio

For VP Strain Engineering and CTO professionals evaluating organ-on-chip & organoids solutions, Emulate represents one option in a market that's becoming increasingly competitive. Alternatives include MIMETAS B.V., each with distinct strengths and trade-offs worth investigating. Key evaluation criteria for this category include integration breadth, time-to-value, and the ability to deliver 5-10x faster design-build-test-learn cycles with AI-guided design in real-world pharmaceutical & drug development environments. As foundry-as-a-service models are democratizing synthetic biology, the window for adopting effective organ-on-chip & organoids tooling is narrowing. Organizations that defer evaluation risk not just falling behind competitors who are already capturing returns, but also facing a more crowded and confusing vendor landscape as additional entrants pile into the market. A structured RFP process, focused on verifiable customer references and hands-on pilots, remains the most reliable path to selecting the right platform.